NCT05640102 - Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia | Biotech Hunter

Enrollment

111

Participants

Timeline

Start Date

March 3, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Waldenstrom Macroglobulinemia

Interventions

DRUG

Zanubrutinib

Dosing and treatment duration are at the discretion of the prescribing physician and in accordance with local labeling

Trial Locations (11)

35805-2606

RECRUITING

Clearview Cancer Institute, Huntsville

36604-1405

RECRUITING

Mitchell Cancer Institute, Mobile

91010-3012

RECRUITING

City of Hope National Medical Center, Duarte

91204-3640

RECRUITING

Los Angeles Cancer Network (Lacn), Glendale

92270-3221

RECRUITING

Eisenhower Medical Center, Lucy Curci Cancer Center, Rancho Mirage

33322-5426

RECRUITING

Brcr Medical Center, Inc, Plantation

39401-7233

RECRUITING

Hattiesburg Hematology and Oncology Clinic, Hattiesburg

89169-3321

RECRUITING

Comprehensive Cancer Centers of Nevada, Las Vegas

11590-5119

COMPLETED

Clinical Research Alliance, Inc, Westbury

00935

RECRUITING

Pan American Oncology Trials, Llc, Rio Piedras

00917

COMPLETED

Auxilio Mutuo Cancer Center, San Juan